What is RayzeBio?
RayzeBio is a clinical-stage radiopharmaceutical company focused on improving outcomes for patients with cancer. The company leverages clinically validated solid tumor targets and proprietary drug conjugate technology to deliver potent alpha-emitting radioisotopes, such as Actinium-225, directly to cancer cells. This targeted approach aims to maximize therapeutic efficacy while minimizing off-target toxicity, addressing a critical need in oncology. Established in 2020, RayzeBio has rapidly advanced its pipeline, positioning itself as a key player in the emerging field of targeted radiotherapeutics.
How much funding has RayzeBio raised?
RayzeBio has raised a total of $418M across 4 funding rounds:
Series A
$45M
Series B
$105M
Series C
$108M
Series D
$160M
Series A (2020): $45M with participation from Versant Ventures GmbH, Samsara Bio-Pharma, and venBio Partners LLC
Series B (2020): $105M led by Viking Global Investors, LifeSci Venture Partners, Logos Capital, Redmile Group, Venrock Healthcare Capital Partners, OrbiMed, Cormorant Asset Management, and Alexandria Venture Investments
Series C (2021): $108M supported by Perceptive Advisors, Versant Ventures, venBio Partners, LifeSci Venture Partners, Viking Global Investors, Cormorant Asset Management, Vivo Capital, HealthQuest Capital, OrbiMed, Redmile Group, Samsara BioCapital, TCG X, Deerfield, Alexandria Venture Investments, and Logos Capital
Series D (2022): $160M featuring Sands Capital, Viking Global Investors, Wellington Management, and Ally Bridge Group
Key Investors in RayzeBio
Perceptive Advisors
Perceptive Advisors is an investment firm founded in 1999, managing substantial assets and focusing on funding innovative healthcare and life sciences technologies.
Versant Ventures
Versant Ventures is a venture capital firm that partners with entrepreneurs to build and fund innovative biotechnology companies globally, with a strong track record in IPOs and M&A.
venBio Partners
venBio Partners is a life sciences investment firm established in 2011, focusing on novel therapeutics for unmet medical needs and partnering with industry leaders to develop innovative medicines.
What's next for RayzeBio?
With the recent influx of capital, RayzeBio is poised to accelerate its clinical development programs and expand its operational capabilities. The substantial enterprise-level backing suggests a strategic focus on advancing its lead drug candidates through late-stage clinical trials and preparing for potential commercialization. This investment will likely fuel further research and development, enhance manufacturing capacity for radiopharmaceuticals, and support the expansion of its scientific and clinical teams. The company's trajectory indicates a move towards becoming a leading force in radioligand therapy, aiming to bring innovative treatment options to patients with significant unmet medical needs.
See full RayzeBio company page
